Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research ...

Plus: Rockville man arrested for filming woman in fitting room at Montgomery mall; Montgomery College launches cybersecurity ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced today that four abstracts with Innate’s drugs in clinical development have been accepted for the American ...

Controlling the entire cell therapy production process—from material receipt to product release—is “essential,” according to AstraZeneca, which says its new $300 million manufacturing facility will be ...

So on that alone, maybe yes. But what might this new US move mean for the industry overall, and for AstraZeneca shares specifically? Analyst Stefan Schneider at Bank Vontobel said it “has the ...

LJ Hooker has facilitated the sale of the 1.73-hectare parcel, made up of three separate lots, on the corner of Mort and North Streets in Rockville for $2.875m. A collection of commercial parcels ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non ...

(Alliance News) - AstraZeneca PLC on Friday said it has received positive data from a trial evaluating Imfinzi as a treatment for patients with high-risk non-muscle-invasive bladder cancer.

It has been a dozen years since Alice in Chains played Welcome to Rockville, long before the festival made its 2021 transition from Jacksonville to Daytona International Speedway. When the veteran ...

As health systems across the Middle East and Africa confront the dual pressures of rising non-communicable diseases (NCDs) and persistent access gaps, AstraZeneca is placing health equity at the ...

AstraZeneca announced on May 6, 2025 that its Calquence (acalabrutinib), a second-generation, selective inhibitor of Bruton’s tyrosine kinase (BTK), was approved in the European Union in combination ...